How do I evaluate whether a bioequivalence study provider is credible and unbiased for a regulated generic program?

To evaluate whether a bioequivalence (BE) study provider is credible and unbiased for a regulated generic program, you want to assess both regulatory quality and independence/integrity. A good provider should be able to generate data that would stand up to scrutiny from FDA, EMA, MHRA, PMDA, or other agencies, and should not have incentives or practices that could distort results.

1) Check regulatory inspection history and compliance

Start with the basics:

• Has the site been inspected by relevant authorities?
  • FDA, EMA/Member State, MHRA, WHO, local national regulators.
• Were there any findings?
  • Warning letters, Form 483 observations, GCP/GxP deficiencies, import alerts, trial suspensions, data integrity issues.
• How recent are the inspections?
  • A clean inspection 8 years ago is less reassuring than one in the last 1–3 years.
• Do they have current accreditations/certifications?
  • GLP/GCP compliance status, ISO certifications if relevant, and local regulatory authorizations.

What to ask for:

• Copies/summaries of inspection reports or remediation letters
• CAPA records for any deficiencies
• Current licenses/registrations for clinical unit, lab, and ethics processes

2) Verify data integrity systems

A credible provider should have strong controls to prevent manipulation or selective reporting.

Look for:

• ALCOA+ principles: attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, available
• Audit trails in all electronic systems
• Source data verification and chain-of-custody
• Validated bioanalytical methods
• Controlled access to raw data and chromatograms
• Deviation management and documented investigations
• Role separation between study conduct, data review, and final reporting

Ask specifically:

• Can you show raw data, not just summary tables?
• How are chromatograms reviewed for reintegration or exclusion?
• Who approves method deviations and protocol deviations?
• How do you prevent unauthorized edits to data?

3) Assess scientific competence

A provider may be compliant but still not scientifically strong enough for a generic program.

Evaluate:

• Experience with your dosage form
  • Immediate-release tablets, MR products, inhalation, transdermal, topical, biologics/complex generics, etc.
• Therapeutic area familiarity
  • Highly variable drugs, narrow therapeutic index products, fed/fasted studies
• Study design expertise
  • Crossover, replicate designs, partial replicate, sequential designs, scaling approaches
• Statistical capability
  • Mixed-effects models, confidence interval analysis, sample-size justification, handling outliers
• Bioanalytical expertise
  • Sensitivity, selectivity, stability, incurred sample reanalysis if applicable

Ask for:

• Examples of similar approved studies
• CVs of key staff
• Statistical analysis plans and sample-size rationale
• List of validated analytes and matrices
• Success rate with regulatory submissions, if they can share it credibly

4) Evaluate independence and conflict of interest

Credibility is not only technical; it’s also about whether they can remain impartial.

Look for:

• Organizational separation between sponsor-facing business development and data review functions
• No payment tied to passing results
  • Avoid any compensation structure that rewards “positive” BE outcomes
• Clear SOPs for blinding
  • Analysts and study personnel should not be able to influence results
• Governance
  • Independent QA unit, independent medical oversight, and external ethics review where appropriate

Red flags:

• Guarantees of “success”
• Willingness to “adjust” borderline data without scientific justification
• Refusal to let you audit raw data
• Overly commercial language about “getting products approved fast” without discussing limitations

5) Review quality management and SOP maturity

A provider with mature systems is more likely to be credible.

Check whether they have:

• Documented SOPs for dosing, sample handling, calibration, method validation, deviations, and reporting
• Training records for all critical staff
• Change control for methods and systems
• Deviation/CAPA trending and root-cause analysis
• Internal audits and QA oversight
• Vendor qualification for third-party labs, couriers, or clinics

Ask to see:

• QA audit schedules
• Example CAPA summaries
• Training matrix for key personnel
• Change-control logs for instrumentation/software

6) Examine study conduct capabilities

For BE studies, execution quality matters as much as paperwork.

Key operational questions:

• How do they manage subject screening, randomization, and confinement?
• How do they ensure protocol adherence during dose administration and sampling?
• What is their sample handling time from collection to processing/freezing?
• How do they maintain cold chain and shipping integrity?
• What is their process for adverse event monitoring and medical escalation?
• How do they manage subject compliance and retention?

Good signs:

• Detailed operational timelines
• Emergency procedures
• Real-time monitoring and documented chain of custody
• Experienced clinical pharmacology staff

7) Validate the analytical lab separately

Sometimes the clinical site is good but the lab is weak, or vice versa.

For the bioanalytical lab, verify:

• Method validation package
• System suitability and calibration procedures
• Run acceptance criteria
• Stability data
• ISR policies and performance
• Instrument maintenance and qualification
• Data review workflows and QA sign-off

Red flags:

• Frequent reanalysis without justification
• High proportion of missing samples
• Poor reproducibility or unexplained concentration shifts
• Inadequate sensitivity for expected PK ranges

8) Ask for transparency on past performance

A credible provider should be able to discuss history without evasiveness.

Useful questions:

• How many BE studies have you completed in the past 2–3 years?
• How many were accepted by regulators without major deficiencies?
• What were the common reasons for study rejection or deficiency letters?
• Have you had any data integrity findings?
• Can you provide de-identified examples of reports and regulatory correspondence?

You are looking for:

• Consistent answers
• Specific corrective actions they took
• Evidence they learn from prior failures

9) Conduct a sponsor audit

Do your own due diligence, ideally before awarding the study.

Audit scope:

• Clinical facility
• Bioanalytical lab
• QA unit
• Data management systems
• Sample storage and shipping
• Key personnel interviews
• Review of one or two completed studies end-to-end

During the audit, inspect:

• Raw source data vs final report consistency
• Deviations and CAPA handling
• Access controls and audit trails
• Equipment qualification and calibration
• Blinding controls
• Subject records and accountability

If you lack internal expertise, use a qualified third-party auditor with BE/GCP/GxP experience.

10) Assess business incentives and contractual protections

Even a competent provider can be biased if incentives are poorly structured.

Protect yourself with contracts that specify:

• Right to audit at any time
• Access to raw data, audit trails, and SOPs
• Immediate notification of serious deviations or inspections
• No study conduct changes without sponsor approval
• Data ownership and archival rights
• Independent QA review
• Conflict-of-interest disclosures
• Termination rights for data integrity concerns

Avoid:

• Performance bonuses tied to study outcome
• Vague deliverables
• Exclusivity clauses that limit your oversight
• “Black box” reporting arrangements

11) Evaluate reputation, but don’t rely on it alone

Reputation helps, but it is not enough.

Check:

• References from regulated sponsors
• Track record in successful submissions
• Presence in industry associations or conferences
• Publication history, if relevant
• Consistency between what they claim and what you can verify

Be cautious:

• Testimonials without specifics
• References that are only provided through business development
• Overreliance on marketing materials

12) Use a simple scoring framework

A practical way to compare providers is to score them across categories:

• Regulatory compliance history
• Data integrity controls
• Scientific expertise
• Bioanalytical capability
• Operational execution
• QA maturity
• Independence/conflict management
• Transparency and audit responsiveness

Score each from 1–5 and require minimum thresholds in critical categories such as:

• No unresolved critical data integrity findings
• Validated analytical methods
• Demonstrated experience in your dosage form
• Full audit access and raw-data availability

Key red flags

Be very cautious if the provider:

• Refuses audits or limits raw-data access
• Has unresolved inspection findings related to data integrity
• Guarantees approval or “passing” results
• Lacks clear SOPs or audit trails
• Uses the same individuals for operations, data review, and final sign-off without independence
• Has unexplained missing data or repeated reanalysis
• Cannot show experience with your specific product type

Bottom line

A credible and unbiased BE provider is one that has:

1. Verified regulatory compliance
2. Strong data integrity controls
3. Relevant scientific and operational experience
4. Independent QA and conflict-of-interest protections
5. Full transparency and auditability

If you want, I can turn this into a vendor qualification checklist or a scorecard template you can use during due diligence.